Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
Binacea Pharma, Inc.
Participants enrolled in this trial will be assigned to one of 6 experimental Arms/cohorts. Depending on their assignment, participants will receive intravenous BNA035, once weekly, in 28 day cycles, at a starting dose or an escalated dose. Escalated doses will be 3, 10, 30, 100 and 200 times the starting dose level.